LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "triple mutated" as a keyword



FLT3 inhibition with midostaurin offsets poor prognosis in NPM1/FLT3/DNMT3a triple-mutated AML

Sign Up to like & get
recommendations! Published in 2025 at "Blood"

DOI: 10.1182/blood-2025-1672

Abstract: Context: FLT3 mutated (FLT3m) AML with co-occurring mutations in DNMT3a and NPM1 (triple mutated) have been identified to be a subset with poor prognosis. However, the evidence for this comes from trials predating the routine… read more here.

Keywords: year; flt3; triple mutated; aml ... See more keywords

Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML.

Sign Up to like & get
recommendations! Published in 2019 at "Blood"

DOI: 10.1182/blood.2018862383

Abstract: FLT3, DNMT3A, and NPM1 are the most frequently mutated genes in cytogenetically normal acute myeloid leukemia (AML), but little is known about how these mutations synergize upon co-occurrence. Here we show that triple-mutated AML is… read more here.

Keywords: cell; triple mutated; dnmt3a npm1; mutated aml ... See more keywords

IL1RAP is an immunotherapeutic target for normal karyotype triple-mutated acute myeloid leukemia

Sign Up to like & get
recommendations! Published in 2025 at "Biomarker Research"

DOI: 10.1186/s40364-025-00769-z

Abstract: Surface antigens of potential clinical significance remain under-characterized in AML. The European Leukemia Network classifies normal karyotype AML (NK-AML) mutated for NPM1 (NPM1c) as a distinct entity associated with favorable outcomes if not associated with… read more here.

Keywords: normal karyotype; triple mutated; aml; nkt aml ... See more keywords

Who benefits from gilteritinib combination therapy amongst FLT3 mut R/R AML? Genomic insights.

Sign Up to like & get
recommendations! Published in 2025 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2025.43.16_suppl.e18522

Abstract: e18522 Background: The outcome of FLT3 mut R/R AML is dismal. Use of Giltertinib monotherapy results in modest benefits with an improvement in EFS (2.8 months) and OS (9.3 months). Triplet (Azacytidine, Venetoclax and Giltertinib)… read more here.

Keywords: therapy; combination; triple mutated; mut aml ... See more keywords